Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.


A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.

Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J.

Sci Transl Med. 2019 Apr 24;11(489). pii: eaar6584. doi: 10.1126/scitranslmed.aar6584.


Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.

Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, Illei G, Tummala R.

Lupus Sci Med. 2018 Nov 26;5(1):e000284. doi: 10.1136/lupus-2018-000284. eCollection 2018.


Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.

Furie R, Wang L, Illei G, Drappa J.

Lupus. 2018 May;27(6):955-962. doi: 10.1177/0961203318758506. Epub 2018 Feb 20.


Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr.

Gastroenterology. 2017 Jul;153(1):77-86.e6. doi: 10.1053/j.gastro.2017.03.049. Epub 2017 Apr 5.


Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S; CD1013 Study Investigators.

Arthritis Rheumatol. 2017 Feb;69(2):376-386. doi: 10.1002/art.39962.


Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R.

Arthritis Res Ther. 2016 Jun 7;18(1):131. doi: 10.1186/s13075-016-1021-2.


Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W; CD1067 study investigators.

Ann Rheum Dis. 2016 Nov;75(11):1909-1916. doi: 10.1136/annrheumdis-2015-208562. Epub 2016 Mar 23.


Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P.

Arthritis Rheum. 2013 Sep;65(9):2368-79. doi: 10.1002/art.38037.


A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y.

Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23.


Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J.

Arthritis Rheum. 2012 Nov;64(11):3666-76. doi: 10.1002/art.34632.


Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice.

Drappa J, Kamen LA, Chan E, Georgiev M, Ashany D, Marti F, King PD.

J Exp Med. 2003 Sep 1;198(5):809-21.


The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations.

Vaishnaw AK, Toubi E, Ohsako S, Drappa J, Buys S, Estrada J, Sitarz A, Zemel L, Chu JL, Elkon KB.

Arthritis Rheum. 1999 Sep;42(9):1833-42.


Fas ligand expression and function in systemic lupus erythematosus.

McNally J, Yoo DH, Drappa J, Chu JL, Yagita H, Friedman SM, Elkon KB.

J Immunol. 1997 Nov 1;159(9):4628-36.


A major role for the Fas pathway in acute graft-versus-host disease.

Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB.

J Immunol. 1996 Dec 15;157(12):5387-93.


Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.

Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB.

N Engl J Med. 1996 Nov 28;335(22):1643-9.


The apoptosis-1/Fas protein in human systemic lupus erythematosus.

Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB.

J Clin Invest. 1994 Mar;93(3):1029-34.


The onset of Fas expression parallels the acquisition of CD8 and CD4 in fetal and adult alpha beta thymocytes.

Andjelić S, Drappa J, Lacy E, Elkon KB, Nikolić-Zugić J.

Int Immunol. 1994 Jan;6(1):73-9.


Supplemental Content

Loading ...
Support Center